Researcher.Life Logo

Lung Cancer: Targets and Therapy : Impact Factor & More

eISSN: 1179-2728pISSN: 1179-2728
JournalOpen Access

Key Metrics

CiteScore
6.5
SNIP
1.15
Recommended pre-submission checks
Powered by Paperpal by Editage

Lung Cancer: Targets and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher DOVE MEDICAL PRESS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2390
Publication Time16
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2008
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 16
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Lung Cancer: Targets and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Lung Cancer: Targets and Therapy

Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
  • 16 Mar 2026
  • Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
  • 1 Feb 2026
  • Lung Cancer (Auckland, N.Z.)
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
  • 6 Jan 2026
  • Lung Cancer: Targets and Therapy
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
  • 25 Dec 2025
  • Lung Cancer: Targets and Therapy
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
  • 16 Dec 2025
  • Lung Cancer: Targets and Therapy
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker
  • 10 Dec 2025
  • Lung Cancer: Targets and Therapy
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
  • 16 Mar 2026
  • Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
  • 1 Feb 2026
  • Lung Cancer (Auckland, N.Z.)
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
  • 6 Jan 2026
  • Lung Cancer: Targets and Therapy
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
  • 25 Dec 2025
  • Lung Cancer: Targets and Therapy
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
  • 16 Dec 2025
  • Lung Cancer: Targets and Therapy
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker
  • 10 Dec 2025
  • Lung Cancer: Targets and Therapy

FAQs on Lung Cancer: Targets and Therapy